Investor Presentaiton

1 How does our Smart Liquid Biopsy technology achieve high performance for MRD? GUARDANT™ CRC Healthy 1,000+ Differentially Methylated Regions GUARDANTREVEAL (Smart Liquid Biopsy) >1,000 alterations Current Medicare- Reimbursed MRD tests 16 48 INVESTOR 20 DAY 23 Low background methylation chemistry Genome- Machine-learning + wide detection + on 1,000s of samples High sensitivity & high specificity 64

View entire presentation